常规铂类化学治疗方案联合二陈汤加减治疗非小细胞肺癌的效果研究

Effect of conventional platinum-based chemotherapy regimen combined with Erchen decoction on non-small cell lung cancer

目的探讨常规铂类化学治疗方案联合二陈汤加减治疗合并痰证的非小细胞肺癌对胰岛素样生长因子结合蛋白-3(IGFBP-3)、血管内皮生长因子(VEGF)表达水平的影响。方法选取2015年1月至2017年1月威海市中心医院中医科收治的92例合并痰证的非小细胞肺癌患者,采用随机数表法随机分为常规治疗组与联合治疗组,每组46例。常规治疗组男25例,女21例,年龄(61.23±3.45)岁,年龄范围为52~77岁。联合治疗组男26例,女20例,年龄(60.19±4.02)岁,年龄范围为51~73岁。比较两组患者临床效果、血清IGFBP-3、VEGF表达水平、生存质量、2年生存率、复发率及安全性。结果联合治疗组患者有效率[45.6%(21/46)]高于常规治疗组[32.6%(15/46)],差异有统计学意义(P<0.05)。治疗后联合治疗组患者血清IGFBP-3[( 925.41±450.82)μg/L]高于常规治疗组[(1 560.41±349.91)μg/L]、VEGF水平[(1 778.61±400.21)pg/ml]低于常规治疗组[(2 175.21±543.20)pg/ml],差异有统计学意义(P<0.05)。联合治疗组生存质量优于常规治疗组,差异有统计学意义(P<0.05)。联合治疗组患者平均生存时间[(22.12±1.34)个月]长于规治疗组[(18.43±1.90)个月],生存率[71.7%(33/46)]高于常规治疗组50.0%[(23/46)],复发率[2.2%(1/46)]低于常规治疗组[15.2%(7/46)],差异均有统计学意义(P<0.05)。两组患者治疗期间不良反应的比较,差异无统计学意义(P>0.05)。结论常规铂类化学治疗方案联合二陈汤加减治疗痰证非小细胞肺癌能获得显著效果,对血清IGFBP-3、VEGF表达水平进行调节,提高生存质量,在延长生存时间方面也有一定的辅助作用。

Objective To investigate and analyze the effect of conventional platinum chemotherapy combined with Erchen decoction in the treatment of non-small cell lung cancer(NSCLC)with phlegm syndrome on the expression levels of insulin-like growth factor-binding protein-3(IGFBP-3)and vascular endothelial growth factor(VEGF). Methods A retrospective study was performed on 92 cases of patients with NSCLC with phlegm syndrome who were admitted from January 2015 to January 2017.Patients were randomly divided into the conventional treatment group and combined treatment group, with 46 cases in each group.In the conventional treatment group, 25 males and 21 females were aged(61.23±3.45)years, ranging from 52 to 77 years old.In the combined treatment group, 26 males and 20 females were aged(60.19±4.02)years, ranging from 51 to 73 years old.Clinical effect, serum IGFBP-3, VEGF expression level, quality of life, 2-year survival rate, recurrence rate and safety were compared between the two groups. Results After treatment, the effective rate of the combined treatment group [45.6%(21/46)] was significantly higher than that of the conventional treatment group[32.6%(15/46)]. After treatment, the serum IGFBP-3 [(1 925.41±450.82)μg/L] in the combined treatment group was higher than that in the conventional treatment group[(1 560.41±349.91)μg/L], and the VEGF level [(1 778.61±400.21)pg/ml] was lower than that in the conventional treatment group[(2 175.21±543.20)pg/ml], and the difference was statistically significant(P<0.05). The quality of life of the combined treatment group was better than that of the conventional treatment group, and the difference was statistically significant(P<0.05). The mean survival time[(22.12±1.34)months)] in the combined treatment group was longer than that in the conventional treatment group[(18.43±1.90)months)], the survival rate[71.7%(33/46)] was higher than that in the conventional treatment group[50.0%(23/46)], and the recurrence rate[2.2%(1/46)] was lower than that in the conventional treatment group[15.2%(7/46)], with statistically significant differences(P<0.05). There was no significant difference in adverse reactions between the two groups(P>0.05). Conclusion Conventional platinum-based chemotherapy combined with Erchen decoction can significantly improve the treatment of non-small cell lung cancer with sputum syndrome.It can regulate the expression levels of serum IGFBP-3 and VEGF, improve the quality of life, and also has a certain auxiliary effect in prolonging the survival time.